of severe sepsis, with >60% of septic patients developing anemia, and 90% of these patients will remain anemic for several weeks (4) .
Anemia in the critically ill patient is a predictor of poor outcome (5) . This " anemia of inflammation" affects patients with chronic infections, autoimmune dis orders, and malignancies, as well as sepsis (6) . Hemoglobin levels of 7-9 g/dL are typical in septic patients (7) and char acterized by microcytic and hypochromic erythrocytes (4, 8) . Despite its high prev alence and significant adverse impact on quality of life, the mechanisms of anemia of inflammation remain unclear (7) .
Patients with sepsis develop signif icant longterm elevations in circulat ing HMGB1 levels that correlate with inhospital mortality (9) . HMGB1 is a The mortality rate is >20%; survivors of severe sepsis have a cumulative 5year mortality of 74% (2, 3) . Anemia, defined as a decrease in the hematocrit and he moglobin, is a frequent complication
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Characterization of Murine Erythropoiesis
To evaluate stress erythropoiesis, spleens were flushed with 1 mL icecold PBS, and cells were expelled using gentle compression. Bone marrow cells were obtained after dislocating two limbs and two long bones. Bones were cleaned and the epiphysis cut. Each diaphysis was then flushed with PBS repeatedly until no obvious macroscopic hematopoietic tissue remained. Flushed cells (splenic and bone marrow) were homogenized into single cell solution, filtered using a 40 μmol/L sterile cell strainer (Fisherbrand®; Fisher Scientific).
To quantitate the degree of eryth ropoiesis in the bone marrow and the spleen of animals, we used positive magnetic sorting with antiCD45 beads (Milteny Biotec). Erythropoiesis was monitored as described previously (21 
Cytokine Determination
Erythropoietin (EPO) and ferritin were determined by enzymelinked immu nosorbent assay (ELISA) according to manufacturer instructions: EPO (R&D Sys tems, cat: MEP00B) and ferritin (Abcam, cat. no. ab157713). The levels of TNF and IL6 were determined using a mouse a multiplex kit (Meso Scale Discovery), according to the manufacturer's instruc tions. HMGB1 levels were measured by immunoblotting analysis as described previously (19) . Briefly, plasma samples were loaded on sodium dodecylsulfatepolyacrylamide gel electrophoresis (SDSPAGE) and electrically transferred to a poly(vinylidene difluoride) (PVDF) in a 0.9% saline solution), both adminis tered subcutaneously. Survival rates in the CLP model are typically between 50 and 70%.
recombinant HMGB1 administration to Healthy BaLB/c Mice Recombinant rat HMGB1 was ex pressed in Escherichia coli and purified as previously described (17) . Recombinant disulfide HMGB1 was prepared as de scribed elsewhere (18, 19) , 500 μg diluted in 650 μL phosphatebuffered saline (PBS) and administered intraperitoneally to healthy BALB/c mice daily for 21 d. Control mice received PBS injections. This dose of HMGB1 induces an inflam matory response that lasts ~24 h. One day after the last injection, blood, bone marrow and spleen were harvested.
administration of anti-HMGB1 Neutralizing Monoclonal antibody
The antiHMGB1 monoclonal antibody (clone 2G7) was generated as previously described (20) . This is a neutralizing an tibody that detects all redox isoforms of HMGB1. It does not need complement activation or Fcreceptor interactions to perform as an HMGB1 antagonist. It does not react with HMGB2. The mono clonal antibody detects an epitope in sequence 46-63 of the box A domain, more specifically around glycine in position 58, since this is the single discriminating residue between HMGB1 and HMGB2 in this sequence. On d 9-11 after surgery, CLP survivors received intraperitoneal injections of either antiHMGB1 mono clonal antibody (50 μg/day in 200 μL PBS) or mouse IgG2b (ESMD Chemicals) as isotype control (15) . Specificity of 2G7 has been previously demonstrated (15, 16) .
Complete Blood Counts
Blood was collected by cardiac puncture and transferred to ethylene diaminetetraacetic acid (EDTA)coated tubes. Complete blood counts were ob tained using the automated hematology analyzer AcT diff (Beckman Coulter). Reticulocytes were determined by flow proinflammatory cytokine that exists in three redox isoforms, termed disulfide, allthiol and sulfonyl, each possessing differential signaling activities (10, 11) . Disulfide HMGB1 binds to the cell sur face receptor complex MD2TLR4 (12) to enhance release of TNF and IL6, cytokines that have been implicated in the onset of anemia of inflammation in sepsis and negatively regulate erythro poiesis (13, 14) . We recently identified HMGB1 as a mediator of persistent mor bidity and mortality in sepsis survivors (15, 16) . Here we show that HMGB1 is both necessary and sufficient to induce anemia in murine sepsis survivors and that HMGB1 is a therapeutic target.
MaTErIaLs aND METHODs

Mice
All experiments were performed in accordance with the National Institutes of Health guidelines, under protocols approved by the Institutional Animal Care and Use Committee of the Feinstein Institute for Medical Research. Male BALB/c mice were purchased from Charles River. Mice were 3-4 months old at the moment of surgery and weighed between 25 and 28 g. Mice were housed in groups of five in a pathogenfree facility in an enriched environment. Ani mals were on a 12h daylight cycle with ad libitum access to water and normal chow. After cecal ligation and puncture (CLP), investigators and technicians from the Feinstein animal facility ascertained animal welfare twice a day.
Induction of sepsis
Severe polymicrobial abdominal sepsis was induced in BALB/c mice by CLP as previously described (15) . Briefly, after isolation of the cecum, we ligated below the ileocecal valve and punctured it once with a 22G needle. Stool (~1 mm) was mechanically extruded, the cecum returned to the abdominal cavity and the wound closed with surgical clips. Resus citation immediately after CLP included 1 mL saline solution, as well as a dose of ImipenemCilastatin (0.5 mg/kg diluted results, we observed that the spleens are macroscopically enlarged (Figure 2A) . Analysis of spleen sections revealed disruption of the normal architecture, with expansion of the red pulp that is characteristic of stress erythropoiesis (24) (Figure 2B ). After depletion of the CD45 pos compartment (that is, lymphoid populations), splenocytes were ana lyzed by flow cytometry on the basis of the expression of the erythroid marker Ter119. Ter119 + cells were then analyzed by CD44 expression and forward scat ter as previously described (21) . CD44, the hyaluronate receptor, presents an expression pattern that decreases over 30fold during terminal erythroid dif ferentiation (25) . The different stages of terminal erythroid differentiation, from pro to orthochromatic erythroblasts, were significantly expanded in the CLP survivors ( Figures 2C, D) . Bone marrow cell mass was reduced, both before and after depletion of the lymphoid compart ment, but was not statistically significant ( Figure 2E ). Flow cytometry analyses revealed significant increases in the eryth roid precursor population with accumu lation of orthochromatic erythroblasts ( Figures 2F, G) . During erythropoiesis, there is progressive expansion and dif ferentiation with one proerythroblast (P) producing two basophilic (B), four poly chromatophilic (Po) and eight orthochro matic (O) erythroblasts (21) . In the CLP animals, we observed that the progres sion toward orthochromatic erythroblasts in the bone marrow is altered, with the ratio becoming 1 (P), 1.8 (B), 5 (Po) and 11.6 (O). This accumulation of latestage cells indicates that defective erythropoi esis contributes to the anemia phenotype and that there is an increased production of red cell precursors in both cellular compartments.
HMGB1 Induces anemia and stress Erythropoiesis in Mice
We then administered rHMGB1 to BALB/c mice for 21 consecutive days and observed the onset of anemia within 7 d, characterized by a signifi cant increase in the reticulocyte count During the first week after CLP, the reticulocyte count was significantly decreased in CLP survivors compared with sham animals ( Figure 1F 
Prolonged experimental adminis tration of recombinant TNF induces anemia and reduces red blood cell sur vival (14) , and IL6 negatively regulates erythropoiesis, in part by inducing hep cidin (13, 22) . However, TNF and IL6 increase only transiently after sepsis onset in patients, returning to normal levels as anemia persists (23) . CLP survivors had a rapid and transient in crease in IL6 and TNF, but circulating levels of those cytokines returned to levels similar to the sham group after d 5 ( Figures 1G, H) . Hepcidin, a master regulator of iron bioavailability, is re duced in response to acute blood loss, resulting in increased intestinal absorp tion of iron (7) . During inflammation, IL6 induces hepcidin, leading to hypo ferrinemia and anemia (13) . Circulating hepcidin was elevated only transiently 7 d after CLP (data not shown). In con trast to other inflammatory mediators, circulating HMGB1 increased after d 7 and remained elevated for at least 28 d (Figure 1I ), a pattern consistent with previous observations that HMGB1 is a lateoccurring mediator of sepsis. This result indicates a role for HMGB1 in sustaining the anemic phenotype in CLP survivors.
To study the mechanism of anemia in mice surviving sepsis, spleen and bone marrow were collected from animals 10 d after the onset of sepsis. We recently demonstrated the expansion of the leu kocyte compartment in the spleen of CLP survivors (15) . In agreement with these immunoblot membrane (BioRad). After blocking, membranes were probed with either specific antiHMGB1 antiserum or purified IgG from antiHMGB1 an tiserum for Western blot analysis. The levels of HMGB1 were determined by reference to standard curves generated with purified HMGB1, and the relative band intensity was quantified by ImageJ (National Institutes of Health).
spleen Histopathology
Whole spleens were harvested and fixed using 4% (vol/vol) paraformaldehydePBS. The samples were then sent to AML Laboratories for processing, slicing and hematoxylin and eosin (H&E) staining. Photomicrographs were obtained on a Zeiss Axio Imager Z.1 with an Axiocam 506 color camera and further processed using Zen software to match exposure and color balance across specimens.
statistics
Data are expressed as mean ± standard deviation (SD). Differences between means were determined by using a two tailed t test. p values <0.05 were consid ered significant.
rEsULTs
HMGB1 Is a Mediator of anemia in sepsis survivors
To study the development of anemia of inflammation during sepsis, we in duced severe sepsis in BALB/c mice by CLP, using an established protocol with survival rates of 50-70% (15) . Com plete blood counts, obtained for up to 28 d after CLP, revealed a significant decrease in hematocrit ( Figure 1A) , hemoglobin ( Figure 1B) and red blood cells ( Figure 1C ) as early as 3 d after the onset of sepsis that persisted for at least 28 d in survivors, except for the number of red blood cells. The anemia was normocytic and normochromic for at least 7 d, thereafter becoming micro cytic and hypochromic, as evidenced by progressive decreases in the mean corpus cular hemoglobin (MCH) and mean cor puscular volume (MCV) (Figures 1D, E) .
administration of anti-HMGB1 Monoclonal antibodies ameliorates anemia in the CLP Model
To evaluate the role of HMGB1 in the anemia of sepsis, mice received neutral izing monoclonal antiHMGB1 antibody (clone 2G7) or isotype control (IgG2b) on d 9-11 after CLP. The rationale for treat ing the mice at this point was to evaluate the effect of neutralizing HMGB1 after anemia onset. Sepsis survivors receiv ing isotype control developed persistent anemia, whereas survivors receiving the antiHMGB1 had similar levels of hemo globin and hematocrit as the sham group ( Figures 4A, B) . Although hemoglobin and hematocrit normalized within days after the administration of antiHMGB1, MCH CLP [1 (P), 1.8 (B), 5 (Po) and 11.6 (O)]. Macroscopic examination of the spleens revealed that injecting HMGB1 induced splenomegaly ( Figure 3E) . Analysis of the spleen showed increased total cellularity (1.9 ± 0.05 × 10 8 cells in the vehicle group p < 0.001) ( Figure 3B ). We also observed an expansion of erythropoiesis in the bone marrow in response to HMGB1, with an accumulation of polychro matophilic and orthochromatic eryth roblasts ( Figures 3C, D) and a ratio of 1 (P), 1.5 (B), 3.9 (Po) and 9.1 (O). The degree of abnormality was clearly less in the rHMGB1treated animals than in Figure 1 . Sepsis survivors develop sustained anemia, as well as a delayed elevation in HMGB1. Mice were subject to CLP to induce severe sepsis, or sham surgery as control. Compete blood counts were performed at prespecified time points (A-F). TNF (G) and IL-6 (H) were measured by multiplex ELISA. HMGB1 was determined by semiquantitative immunoblotting (I). Data are expressed as mean ± SD (n = 4-5 mice/group). *p < 0.05, **p < 0.01, ***p < 0.001 versus sham.
marrow of the CLP animals. Indeed, during normal terminal erythroid dif ferentiation, three mitoses lead to the production of eight orthochromatic erythroblasts from one proerythroblast. Therefore, a ratio of 1:2:4:8 is normally observed under steadystate conditions. In the CLP model, however, we ob served a ratio of 1:1.8:5:11.6, suggesting that the defect occurs between basophilic dysfunctions (16). Our present study reveals a novel role for HMGB1 in the pathogenesis of anemia of inflammation in sepsis survivors. Anemia can result from increased red cell destruction or defective red cell pro duction. Although we did not measure red cell survival in our murine model of sepsis survivors, we did observe that erythropoiesis is defective in the bone remained lower in CLP survivors than in the sham group 3 wks after CLP, indepen dent of treatment (data not shown). MCV showed a trend to normalizing in the treated group (data not shown).
DIsCUssION
HMGB1 is a mediator in the immune pathogenesis of severe sepsis (18, 20, 26) and also induces renal (27) and cognitive elevated thereafter, suggesting a role for HMGB1 in the chronic phase. To evaluate this possibility, we adminis tered recombinant HMGB1 for 21 d and observed an increase in the reticulocyte count as well as splenomegaly and stress erythropoiesis. We also observed a reduction in total hemoglobin as well as MCH, a similar pattern to the one observed in CLP survivors, where hypo chromic anemia developed before micro cytosis. This result suggests that HMGB1 may induce anemia by interfering with hemoglobin homeostasis. In the bone marrow compartment of animals re ceiving HMGB1, we observed increased populations of all terminal erythroid stages, and the ratios from pro to orthochromatic were closer to normal [1 (P), 1.5 (B) 3.9 (Po), 9.1 (O)], indicating that rHMGB1 induces an increase in the number of mitoses.
Monoclonal antiHMGB1 antibodies have been studied in animal models of sepsis (20) , endotoxin (31), ischemia reperfusion (32), chronic infectious arthritis (33), pain and transplanta tion (34) . Here, the administration of a monoclonal antiHMGB1 antibody (2G7) conferred significant protection against anemia, indicating that HMGB1 is neces sary for pathogenesis of anemia in sepsis survivors.
CONCLUsION
Our results suggest a novel role for HMGB1 in the pathogenesis of anemia of inflammation in severe sepsis survivors and that HMGB1 may be a therapeutic target in the treatment of anemia of inflammation. Together, these results define a new model of anemia similar to the clinical scenario (4), which can be targeted with a monoclonal antibody toward therapeutic advantage in sepsis survivors.
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This work was supported by the National Institute of General Medical Sciences (R01GM57726 and R01GM62508 to KJ Tracey), the National Institute of Allergy and Infectious Diseases decreasing rapidly before manifestation of anemia, suggesting a role for IL6 only in the early stages preceding the onset of anemia. Hepcidin is another import ant mediator in anemia of inflammation and, during systemic inflammation, hepcidin production leads to a reduction in iron availability for erythropoiesis (30) . In the CLP model, we found that the hepcidin levels were only transiently increased, going back to normal within 7 d after surgery. Moreover, the admin istration of rHMGB1 failed to induce a significant increase in circulating hepci din, together suggesting that hepcidin does not play a significant role in the prolonged phase of anemia after sepsis.
Plasma levels of HMGB1 were not significantly increased for the first 7 d after CLP, but they remained persistently and orthochromatic stages, with in creased numbers of mitotic events. Data collected 3 wks after CLP revealed that hematologic recovery is occurring be cause red blood cell numbers return to normal levels. This result is consistent with increased production, although resulting in smaller red cells containing less hemoglobin. This step produces a microcytic and hypochromic phenotype that persists in sepsis survivors.
Inflammatory cytokines have been implicated in the anemia of inflam mation. Prolonged administration of recombinant TNF induces anemia and reduces red blood cell survival (14, 28) . IL6 negatively regulates erythropoiesis, in part by inducing hepcidin (13, 22, 29) . In the CLP model, IL6 peaked 24 h after CLP, with plasma concentrations Figure 4 . Neutralizing HMGB1 reverses anemia in sepsis survivors. CLP survivors were randomly assigned to receive 50 μg/mouse/day of either neutralizing anti-HMGB1 mAb (2G7) or isotype control on d 9-11 after CLP. Whole blood was collected on d 21 or 28 after CLP (4 and 10 d after the last dose of 2G7). Administration of 2G7 rescued septic mice from anemia, as determined by evaluation of the hemoglobin (A) and hematocrit (B) parameters. Data are mean ± SD (n = 4-5 mice/group). *p < 0.05, **p < 0.01, ***p < 0.001.
